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Abstract
In efforts to develop an effective vaccine, sterilizing immunity to primate lentiviruses has only been achieved by the use of live
attenuated viruses carrying major deletions in nef and other accessory genes. Although live attenuated HIV vaccines are unlikely
to be developed due to a myriad of safety concerns, opportunities exist to better understand the correlates of immune
protection against HIV infection by studying rare cohorts of long-term survivors infected with attenuated, nef-deleted HIV
strains such as the Sydney blood bank cohort (SBBC). Here, we review studies of viral evolution, pathogenicity, and immune
responses to HIV infection in SBBC members. The studies show that potent, broadly neutralizing anti-HIV antibodies and robust
CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC
members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression
of HIV infection in another subset. However, a persistent T-helper proliferative response to HIV p24 antigen was associated
with long-term control of infection. Together, these results underscore the importance of the host in the eventual outcome of
infection. Thus, whilst generating an effective antibody and CD8+ T-cell response are an essential component of vaccines aimed
at preventing primary HIV infection, T-helper responses may be important in the generation of an effective therapeutic vaccine
aimed at blunting chronic HIV infection.
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Introduction
Despite considerable effort, all attempts to develop an
effective human immunodeficiency virus (HIV) vaccine
based on subunit or prime-boost strategies have failed to
elicit sterilizing immunity and protect against infection
with wild type virus (reviewed in [1-3]). Current World
Health Organization estimates indicate 42 million people
are infected with HIV and approximately 20 million have
died from AIDS. Approximately 5 million new infections
occur annually. The overwhelming majority of these indi-
viduals live in developing countries with little or no access
to potentially lifesaving antiretroviral therapies. Moreo-
ver, HIV is predicted to become the leading burden of dis-
ease in middle and low income countries by 2015 [4].
Thus, the need for an effective preventative and/or thera-
peutic HIV vaccine has never been more urgent.
Since the discovery of HIV nearly 25 years ago, there have
been significant advances in our knowledge of HIV immu-
nology (reviewed in [5-7]). As early as 1990 subunit vac-
cines based on the HIV envelope protein were developed,
based on the observation that vaccinated chimpanzees
were protected against homologous HIV challenge [8].
However, it is unlikely that such vaccines will ever be able
to illicit immune responses sufficient for protection
against heterologous HIV strains and, in fact, these
approaches have failed repeatedly in animal models. In
addition, HIV envelope protein-based vaccines were not
efficacious in 2 phase III vaccine trials in humans [9-12].
More sophisticated vaccine approaches have targeted cel-
lular immunity by the development of DNA prime-boost
strategies, and have achieved strong stimulation of anti-
body and cytotoxic T-lymphocyte (CTL) responses in
monkeys. However, despite robust immunological
responses, these strategies have ultimately failed to protect
against challenge infection. A better understanding of the
correlates of immune protection against HIV infection
would greatly assist efforts to develop an effective HIV vac-
cine [13,14].
In addition to envelope and DNA prime-boost vaccines,
various other strategies have been adopted in HIV vaccine
development including the use of recombinant viral and
bacterial vectors, synthetic peptides, live attenuated virus,
and whole inactivated HIV particles. These strategies have
been reviewed in detail recently [1-3,15], and are summa-
rized in Figure 1. Other innovative vaccine strategies that
have been recently explored include the use of peptide-
loaded dendritic cells [16], and non-infectious viral parti-
cles surface-engineered to produce antigen presenting par-
ticles that mimic antigen presenting cells [17] to induce
cellular immune responses. To date, sterilizing immunity
to primate lentiviruses has only been achieved by the use
of live attenuated simian immunodeficiency virus (SIV)
and chimeric simian-HIV (SHIV) vaccines carrying major
deletions in the nef gene and other accessory genes [18-
21]. Passive infusion of broadly-neutralizing monoclonal
antibodies in HIV animal models have also been shown
to confer complete protection against challenge infection
[22-25]. This provides proof of principle that protection
against infection is possible with use of the appropriate
antigen. However, nef-deleted virus is unlikely to be con-
sidered safe enough for use as a HIV vaccine, either
because immunization may pose an immediate risk to
individuals with weak immune systems, or because the
attenuated vaccine strain could eventually evolve to a
more pathogenic form [14]. Both of these outcomes have
been demonstrated in macaque studies, whereby some
animals vaccinated with nef-deleted SIV progressed to
AIDS in the absence of wild type virus challenge infection
[26,27]. Moreover, some individuals infected with nef-
deleted HIV strains eventually experience CD4+ T-cell loss
after many years of asymptomatic infection [28-31].
Nonetheless, studies of long-term survivors (LTS) natu-
rally "vaccinated" with nef-deleted HIV, such as the Syd-
ney blood bank cohort (SBBC) [32] and other rare cohorts
[33-37], may provide unique insights into protective anti-
body and CTL responses, which may assist HIV vaccine
development [14].
Epidemiology and Clinical History of the Sydney blood 
bank cohort
The SBBC consists of 8 individuals (subjects C98, C54,
C49, C64, C18, C135, C83 and C124) who became
Various approaches for HIV vaccine development Figure 1
Various approaches for HIV vaccine development. 
The various approaches used in past and present HIV vaccine 
strategies that are summarized here have been described in 
detail previously [1-3, 15].Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
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infected with an attenuated strain of HIV via contami-
nated blood products from a common blood donor (sub-
ject D36) between 1981 and 1984 [30,32,38]. The SBBC
blood transfusion recipients have been referred to as
recipients 7, 13, 12, 9, 10, 4, 8, and 5, respectively, in one
previous study [30] and subjects A (C18), B (C64), C
(C98), D (C54), E (C49) and F (C83) in an earlier publi-
cation [38]. Viral attenuation has been attributed to gross
deletions in the nef/long terminal repeat (LTR) region of
the HIV genome [32]. The clinical history and laboratory
studies of the subjects from the first identification as SBBC
members through 1998 has been described previously
[30], and a detailed update of the clinical and laboratory
data through 2006 has been described recently [39].
Briefly, despite being infected from a single source, SBBC
members now comprise slow progressors (SP) who have
eventually experienced decline in CD4 T-cells after many
years of asymptomatic infection (subjects D36, C98,
C54), and "elite" long-term nonprogressors (LTNP) who
have had stable CD4 T-cell counts and low or below
detectable plasma HIV RNA levels for more than 20 years
without antiretroviral therapy (ART) and remain asymp-
tomatic (subjects C49, C64, C135) [28,30,31]. Five SBBC
members have died of causes either unrelated to- or not
directly related to HIV infection (C98, C54, C18, C83,
C124) (Table 1). The SBBC therefore provides a unique
opportunity to study the pathogenesis of, and immune
responses to nef-deleted HIV infection in a naturally
occurring human setting.
HIV isolates and viral phenotypes
To determine whether changes in viral phenotype were
occurring in SBBC members, HIV isolation was attempted
from peripheral blood mononuclear cells (PBMC) col-
lected longitudinally from all subjects except C124 and
C83 [28,40], by selected PBMC coculture techniques
[40,41] (Table 2). For subjects with detectable but low
HIV RNA levels (D36, C54, C98, C18), more than 10 HIV
isolates were obtained from each of D36, C54 and C98
over a 5 to 6 year period between November 1994 and
November 2000 [40]. Three HIV isolates were obtained
from C18 over an 8 month period between July 1993 and
March 1994. For subjects with consistently undetectable
HIV RNA levels (C49, C64, C124, and C135), a single iso-
late was obtained from C64 from PBMC collected in Feb-
ruary 1996. This was despite isolation attempts from 16
additional PBMC collections between November 1995
and March 2001 [40]. All isolates carried similar but dis-
tinct deletion mutations in the nef gene and LTR region
[28,29,32,42], and were unable to synthesize Nef proteins
detectable by Western blotting or immunofluorescence
staining of infected cells (D. McPhee and A. Greenway,
unpublished data). No isolates were obtained from longi-
tudinal samples of PBMC collected from C49 or C135
over a 4 to 7 year period between February 1994 and
October 2000, or from a single sample of PBMC obtained
from C124 in March 1993 [40]. Thus, success of isolating
nef-deleted HIV from SBBC members was strongly
dependent on the presence of detectable plasma HIV RNA
levels, with few exceptions.
Table 1: Clinical history of SBBC members
Subject Sex Date of 
Birth
Date 
Transfused
Antiretroviral Drugsa Clinical History and other informationa
D36 M 6/4/1958 N/A; infected 
with HIV-1 
sexually, 12/1980
ABC, AZT, NVP (1/1999-
9/2004) ABC, NVP, 3TC 
(9/2004-present)
Diagnosed with moderate HIVD, 12/1998; SP.
C98 M 7/11/1937 1/2/1982 D4T, NVP, IND (11/1999-
death)
Prednisone since 1995 for asthma; died 3/30/2001 from 
bronchial amyloidosis; death not related to HIV; SP.
C54 M 2/17/1928 7/24/1984 None IDDM; HCV; surgery for colon cancer in 1995; died 8/28/
2001 from myocardial infarct; death not related to HIV; SP.
C49 F 6/9/1954 6/11/1984 None Diagnosed with age-onset diabetes in 2004, managed by 
diet; chronic alcoholism; LTNP.
C64 F 3/20/1926 5/4/1983 None Hypertension; hypercholesterolemia; LTNP.
C135 M 2/23/1946 2/11/1981 None CCR5∆32 heterozygote; HLA-B57 positive; LTNP.
C18 M 10/12/1912 8/31/1983 None Severe coronary atherosclerosis; died 11/1995 from 
bacterial pneumonia; death not related to HIV; LTNP.
C83 F 12/21/1964 12/30/1982 None Prednisone since 1982 for SLE; intermittent 
cyclophosphamide, azathioprine, hydrocortisone; died 
from combined PCP and pneumococcal pneumonia 4/1987; 
uncertain if death was HIV related; HIV Progression status 
uncertain
C124 F 9/30/1917 4/29/1981 None Died from metastatic gastric cancer 10/1994. Death not 
related to HIV; HIV Progression status uncertain.
Dates shown are day/month/year. M, male; F, female; ABC, abacavir; AZT, zidovudine; NVP, nevirapine; 3TC, lamivudine; N/A, not applicable; 
HIVD, HIV associated dementia; SP, slow progressor; LNTP, long-term nonprogressor; IDDM, insulin-dependent diabetes melitis; SLE, systemic 
lupus erythematosus. aThese data have been reported previously [30, 39].Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
Page 4 of 13
(page number not for citation purposes)
Table 2: Phenotypes of nef-deleted viruses isolated from SBBC members, and corresponding laboratory data
Subject Virus isolate Date Years post-
infection
CD4 cells 
(cells/µl)
HIV RNA 
(copies/ml)
Replication in 
PBMC
Coreceptor 
usage
D36 D36II 6/5/95 14.4 N/A 1400 ++ CCR5, CXCR4, 
(CCR2b)
D36III 8/2/96 15.2 609 1100 ++ NT
D36IV 10/4/96 15.3 504 7700 ++ NT
D36V 9/7/96 15.6 414 2600 ++ NT
D36VI 23/10/96 15.8 432 1100 ++ NT
D36VII 30/1/97 16.1 361 3200 ++ NT
D36VIII 20/5/97 16.4 540 4000 ++ CCR5, CXCR4, 
(CCR2b)
D36IX 23/12/97 17.0 390 7500 ++ CCR5, CXCR4, 
(CCR2b)
D36X 15/7/98 17.6 325 N/A ++ NT
D36XI 22/1/99 18.1 N/A N/A ++ CCR5, CXCR4, 
(CCR2b)
D36XVI 8/11/00 19.9 N/A BD ++ CCR5
C18 C18(2) 26/7/93 9.8 N/A N/A +++ CCR5, (CCR3, 
Gpr15)
C18(3) 14/10/93 10.1 N/A N/A +++ NT
C18(4) 7/3/94 10.5 N/A 2804 +++ CCR5, (CCR3, 
Gpr15)
C54 C54III 7/11/94 10.3 2006 8200 +/- CCR5, (CCR2b, 
CCR3)
C54IV 21/6/95 10.9 1504 3000 +/- NT
C54 V 20/12/95 11.4 1054 400 +/- NT
C54VI 4/3/96 11.7 1188 1500 +/- NT
C54VII 19/6/96 11.9 972 3600 +/- NT
C54VIII 16/9/96 12.2 1120 1800 +/- CCR5, (CCR2b, 
CCR3)
C54X 3/3/97 12.7 882 3400 +/- NT
C54XI 14/5/97 12.8 1286 N/A +/- NT
C54XII 11/8/97 13.1 1419 1700 +/- NT
C54XIII 17/11/97 13.3 1054 N/A +/- NT
C54XIV 5/5/99 14.8 1288 1200 +/- CCR5, (CCR2b, 
CCR3)
C54XV 6/3/00 15.7 840 1600 +/- NT
C98 C98II 7/12/94 12.9 426 1000 ++ CCR5, (CCR3)
C98III 9/10/95 13.8 576 670 ++ NT
C98IV 7/2/96 14.1 435 200 ++ NT
C98V 22/5/96 14.3 693 290 ++ NT
C98VI 7/8/96 14.6 512 330 ++ CCR5, (CCR2b, 
CCR3)
C98VII 4/11/96 14.8 646 690 ++ NT
C98VIII 31/1/97 15.0 629 770 ++ NT
C98IX 7/5/97 15.3 529 760 ++ NT
C98X 27/8/97 15.6 612 170 ++ NT
C98XI 26/11/97 15.8 400 N/A ++ NT
C98XII 30/9/98 16.7 N/D N/A ++ NT
C98XIII 3/3/99 17.2 476 N/A ++ NT
C98XIV 9/11/99 17.8 585 BD ++ CCR5, (CCR2b, 
CCR3)
C64 C64IV 28/2/96 12.8 850 BD +/- CCR5
Dates shown are day/month/year. CD4 cells were measured by flow cytometry. Plasma HIV-1 RNA was measured by COBAS Amplicor HIV-1 
Monitor Version 1.0 (Roche Molecular Diagnostic Systems, Branchburg, N.J.) prior to July 1999 and Version 1.5 after July 1999. HIV-1 RNA levels < 
400 copies/ml (Version 1) or < 50 copies/ml (Version 1.5) were considered below detection. BD, below detection; N/A, not available; NT, not 
tested. +++, replication kinetics similar to wild type primary HIV strains; ++, reduced levels of replication and/or delayed replication kinetics 
compared to wild type primary HIV strains; +/-, levels of HIV replication barely detectable or not detectable by RT assays, but detectable by 
measurement of extracellular p24 antigen [40].Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
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When compared with wild type HIV isolates and isogenic
controls with mutations in nef, replication capacity of
SBBC isolates in PHA-activated PBMC was found to be
consistent over time by viruses isolated from a particular
subject, but heterogenous between subjects and fell into 3
distinct phenotypes [28,40] (Table 2). Viruses isolated
from C18 replicated rapidly to high levels similar to wild
type HIV; viruses isolated from D36 and C98 replicated to
lower levels; and viruses isolated from C54 and C64 were
barely able to replicate to detectable levels. In contrast, all
isolates replicated to equivalent levels in the Cf2-luc
reporter cell line [41,43,44] expressing CD4, CCR5 and
CXCR4. Thus, SBBC isolates except those from C18
appear to have attenuated replication capacity in PHA-
activated PBMC. Inhibiting the in vivo replication of HIV
in D36 by HAART demonstrated a prolonged in vivo virion
half life, with a first-phase slope of decline of HIV RNA
0.18/day [45] which is slower than that seen in all previ-
ously studied individuals infected with wild-type HIV
after commencement of ART [46-49]. Thus, the replica-
tion kinetics of D36 virus appears to be attenuated both in
vitro and in vivo.
Analysis of coreceptor usage in transfected Cf2-Luc cells
[41] showed that all isolates used CCR5 (R5) as the pri-
mary coreceptor for HIV entry, except viruses isolated
from D36 prior to commencement of HAART which were
dual tropic and used CCR5 and CXCR4 (R5X4) [28,40]
(Table 2). These results showed that nef-deleted HIV was
capable of undergoing a coreceptor switch from R5 to
R5X4 in vivo. An isolate obtained from D36 after com-
mencement of HAART was CCR5-restricted and had fea-
tures of an early archived HIV variant, but was genetically
similar to HIV present in a CSF sample obtained from
D36 during HIV-associated dementia (HIVD) [28]. Thus,
for D36, HIV present in CSF during HIVD was likely to be
an early variant that underwent compartmentalized evo-
lution in the CNS. Moreover, we showed for the first time
that nef-deleted HIV is inherently capable of undergoing
compartmentalized evolution in the CNS and causing
neurologic disease in humans [28]. Stepwise quasispecies
diversity was observed in SBBC SP, whereas C49 displayed
stable quasispecies diversity most similar to early variants
in the SBBC (B. Herring et al., manuscript submitted).
Extended analysis of alternative coreceptor usage showed
that D36 and C54 isolates could use CCR2b, C18 and C54
isolates could use CCR3, and C18 isolates could use
Gpr15 for HIV entry, albeit at low levels [40] (Table 2).
Whether expanded usage of alternative HIV coreceptors
by SBBC isolates contributes to HIV pathogenesis in these
individuals is uncertain, but the unique signature of core-
ceptor usage for viruses isolated from different SBBC
members suggests independent evolution for each virus
after infection of each cohort member. This interpretation
is consistent with results of Env heteroduplex tracking
assays, Env heteroduplex mobility assays and Env V1V2
length polymorphism assays which also demonstrated
independent evolution of HIV Env in each subject ([50],
and B. Herring et al., manuscript submitted).
Changes in HIV pathogenicity
To better understand changes in pathogenicity which may
have contributed to HIV progression in D36, Jekle et al
[51] used an ex vivo human lymphoid cell culture system
to analyze the ability of 2 HIV viruses isolated from D36
to deplete CD4+ T-cells; one isolated in 1995 prior to the
onset of AIDS (D36II) and another isolated in 1999 after
the onset of disease progression (D36XI) (Table 2).
Although both D36 isolates were less potent in depleting
CD4+ T-cells than reference X4 and R5X4 isolates with
intact nef genes, the 1999 isolate induced greater levels of
CD4+ T-cell cytotoxicity than the 1995 isolate. Differences
in CD4+ T-cell cytotoxicity between the 2 isolates were
evident in CD4+/CCR5- cells, but not evident in CD4+/
CCR5+ cells suggesting an increased ability to use CXCR4
by the 1999 isolate. Further studies with the CXCR4
inhibitor AMD3100 showed that, although both isolates
were functionally R5X4 [28,40] (Table 2), the 1999 isolate
had preferential use of CXCR4 whereas the 1995 isolate
had preferential use of CCR5 for HIV entry. These studies
showed evolution of R5X4 strains in D36 to a variant with
higher cytopathic potential that was associated with
increased use of CXCR4 in vitro and HIV progression in
vivo.
Consistent with results of the study by Jekle et al [51], we
showed alterations in HIV cytopathicity by sequential
D36 isolates in cultures of monocyte-derived macro-
phages (MDM). Compared with the highly macrophage
tropic R5 ADA and R5X4 89.6 isolates, all D36 viruses rep-
licated in MDM to low levels and had delayed replication
kinetics [52]. There was no evidence of increased HIV rep-
lication in MDM by virus isolated from D36 after HIV pro-
gression. However, in support of the results obtained by
Jekle et al [51], the 1999 isolate caused extensive cyto-
pathicity in MDM similar to that present in cultures
infected with ADA or 89.6, characterized by the presence
of many syncytia [52]. In contrast, earlier D36 isolates
caused only few or occasional syncytia in MDM despite all
D36 viruses replicating in MDM to similar levels. Thus,
increased cytopathicity in MDM by the 1999 D36 isolate
is most likely due to intrinsic pathogenic features of the
Env that increase fusogenicity, similar to that which has
been observed by particular neurotropic R5 and R5X4
viruses [53-55]. The increased Env fusogenicity may have
contributed to greater cytopathicity by the 1999 D36 iso-
late and HIV progression in D36. Further studies to eluci-
date the molecular determinants of D36 Env that are
associated with increased fusogenicity are in progress.Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
Page 6 of 13
(page number not for citation purposes)
T-cell pathogenesis
The effect of long-term infection with nef-deleted virus on
CD4+ T cells was studied in detail for six SBBC members
[56]. Careful comparison with age- and transfusion-
matched controls revealed the surprising result that SBBC
members had an increased number of circulating
CD45RO+ memory CD4+ T cells. This was unexpected,
since these CD4+ T cells are widely believed to represent
the main target of cytopathic HIV infection [57-60]
(reviewed in [61]), and loss of these cells ultimately leads
to acquired immunodeficiency. Therefore, this result is
consistent with the hypothesis that nef-deleted HIV has
reduced pathogenicity in vivo.
Nevertheless, in the SBBC subjects studied with detectable
plasma viral load, C54 and C98, there was concomitant
elevation of CD8+ T cell activation, whereas the SBBC
subjects with undetectable plasma viral load, C49, C64
and C135 had normal levels of CD8+ T cell activation
[56]. Therefore, within the SBBC, the situation was similar
to the strong correlation seen between plasma viral load
and CD8+ T-cell activation in subjects infected with wild
type HIV [62]. Furthermore, as described above, subjects
D36, C98 and C54 exhibited a clear CD4+ T cell decline,
albeit at a relatively slow rate [28-30]. This interesting
finding argues that pathogenicity within the SBBC was
more closely correlated with levels of viral replication (as
assessed by plasma viral load) and CD8+ T-cell activation
than with viral pathogenicity dictated by the presence or
absence of nef. This finding likely represents the ability of
host factors to modulate the pathogenicity of nef-deleted
HIV-1 [63,64]. CD8+ T cell activation may reflect lym-
phocyte turnover during HIV infection, which has been
proposed to lead to disruption of normal homeostasis
and eventual consumption of both memory and naïve
CD4+ T cells [65,66]. However, we did not find evidence
of dramatically increased CD4+ T cell turnover in these
subjects, as determined by expression of Ki-67 as a marker
of cell proliferation [56].
Evolution of nef/LTR sequence
To determine whether an evolving nef/LTR sequence con-
tributed to HIV progression in D36 and C98, we under-
took a detailed longitudinal analysis of nef  and LTR
sequence changes occurring in D36, C98, C49, C54 and
C64 over a 4 to 10 year period [29]. Sequential analysis of
nef/LTR demonstrated a gradual loss of nef sequence that
differed in magnitude between subjects. A large deletion
of 128 bp emerged in D36 effectively removing the entire
nef gene with the exception of the region surrounding the
nef start codon, the polypurine tract which contains termi-
nal signals for HIV integration, and a 90 bp region of the
nef/LTR overlap region surrounding the negative regula-
tory element. The pattern of nef/LTR sequence loss in C98
was remarkably similar to that of D36. The pattern of nef
/LTR sequence loss in C54 was also similar, but less exten-
sive than that observed in D36 and C98. However, the
additional loss of nef/LTR sequence in C64 was compara-
tively minimal. These data are illustrated in Figure 2,
where the nef/LTR sequences cloned from the earliest
available and most recent blood samples of these subjects
are compared. A more detailed longitudinal analysis of
nef/LTR sequences in these subjects has been reported in
Churchill et al [29]. Thus, viruses harboured by D36, C54,
C98 and C64 appeared to be evolving in a convergent
fashion toward a highly deleted, minimal nef/LTR struc-
ture containing only sequence elements that are abso-
lutely essential for HIV replication [29]. The convergent
Convergent evolution of SBBC nef/LTR sequences Figure 2
Convergent evolution of SBBC nef/LTR sequences. 
Comparisons of the genomic structures of the nef/LTR 
sequences cloned from the earliest available and most 
recently obtained PBMC samples of D36, C98, C49, C54 and 
C64 are shown. The genomic structures are compared to 
wild type HIV (NL4-3). Numbers refer to nucleotide posi-
tions in NL4-3. Black boxes represent intact sequence, and 
gaps represent deletions. Grey blocks represent sequence 
areas containing alterations of NF-κB and Sp-1 binding sites 
in the LTR. The dates shown represent the times when 
PBMC were collected for analysis. PPT, polypurine tract; 
NRE, negative regulatory unit. This figure has been published 
previously [29], and is reproduced here with permission 
from the American society for microbiology.Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
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nature of the nef/LTR sequence changes implies the pres-
ence of strong selection pressures that maintains the abil-
ity of defective HIV genomes to persist in vivo. The highly
evolved nef/LTR sequences harboured by D36, C54 and
C98 were strikingly similar to those that remained domi-
nant in C49 for at least 10 years (Fig. 2) [29]. Thus, the
highly evolved nef/LTR structure appears to be stable, and
in the case of C49 does not increase pathogenicity. How-
ever, taken together the results suggest the in vivo patho-
genicity of nef-deleted HIV harboured by SBBC members
is dictated by factors other than those that impose a uni-
directional selection pressure on the nef/LTR region of the
HIV genome. Due to the changes in the nef/LTR region,
these other presumably host factors become more impor-
tant in terms of disease outcome. This is exemplified by
the marked variation from no disease progression with no
detectable virus replication (C49 and C64), to no progres-
sion with a low viral load (C54), through to slow progres-
sion (D36 and C98).
Reversion to pathogenicity by nef-deleted SIV has been
associated with restoration of a truncated Nef protein
[26], acquisition of further deletions in the nef/LTR over-
lap region [67], and/or duplications of NF-κB binding
sites in the LTR [67]. In contrast to the SIV studies, the in
vivo evolution of nef-deleted HIV in SBBC members was
unidirectional toward a smaller nef/LTR sequence and the
majority of the additional sequence loss was within the
nef-alone region [29]. Furthermore, none of the clones
were capable of encoding Nef. Together, these results sug-
gest improved viral replication by further deleting rem-
nants of the nef  gene. In addition, the presence of
duplicated NF-κB binding sites in the LTR was not associ-
ated with clinical status of the SBBC subjects. Therefore, it
is likely that viral factors that modulate the in vivo patho-
genicity of nef-deleted HIV will be distinct from those in
nef-deleted SIV. Interestingly, the unidirectional evolution
toward the minimal nef/LTR sequence observed in SBBC
members was strikingly similar to the pattern of evolution
in a slow progressor infected with a nef/LTR-deleted vari-
ant of HIV circulating recombinant form 01_AE [34]. The
convergent pattern of nef/LTR evolution among viruses
harboured by SBBC members is therefore unlikely to be
due to a unique property of the infecting strain, but rather
a positive selection that is common across clades.
Changes in transcriptional activity
Viruses harbored by SBBC members contain unique alter-
ations of NF-κB and Sp-1 binding sites in the LTR that may
affect transcriptional activity and thus, replication capac-
ity [28,29,32]. Therefore, we examined the nucleotide
sequence and transcriptional activity of nef/LTR clones
obtained sequentially from D36 blood samples and from
D36 CSF obtained during HIVD, to determine whether
changes in LTR activity may contribute to neuropathogen-
esis of nef-deleted HIV-1 infection [68]. We found that the
transcriptional activity of CSF-derived nef/LTR clones was
up to 4.5-fold higher than blood-derived clones isolated
before and during HIVD when tested under basal, PMA-
and Tat-activated conditions. The presence of duplicated
NF-κB and Sp-1 binding sites or a truncated nef sequence
in blood-derived nef/LTRs was not sufficient to mediate
large increases in transcriptional activity. However, CSF-
derived nef/LTRs had duplicated NF-κB and Sp-1 binding
sites coupled with a truncated nef sequence, which formed
a regulatory unit that significantly enhanced LTR tran-
scription [68].
Previous studies showed that LTR variants with aug-
mented transcriptional activity enhance replication of
HIV [69]. Therefore, to determine whether D36 nef/LTRs
affect replication capacity of HIV in vitro, we produced and
characterized full-length chimeric molecular clones of
HIV NL4-3 carrying the nef/LTR nucleotide sequence of
blood-derived D36 nef/LTRs or the CSF-derived D36 nef/
LTR [68]. We examined the capacity of chimeric NL4-3
viruses carrying D36 nef/LTRs to replicate in PBMC com-
pared with wild type NL4-3 and the NL4-3∆Nef deletion
mutant [70]. Compared to wild type NL4-3, chimeric HIV
containing the nef/LTR sequence of blood derived D36
viruses had attenuated replication kinetics, similar to
NL4-3∆Nef. In contrast, chimeric HIV containing the nef/
LTR of D36 CSF had enhanced replication capacity com-
pared to wild type NL4-3. Thus, the nef/LTR derived from
CSF of D36, which had augmented basal, PMA- and Tat-
activated transcriptional activity compared to wild type
and blood-derived D36 nef/LTRs, augmented replication
of HIV in PBMC. Together, our results suggest unique fea-
tures of the CSF-derived nef/LTR restore efficient replica-
tion capacity of nef-deleted HIV in PBMC by enhancing
transcription. The results further suggest that nef and LTR
mutations that augment transcription may contribute to
neuropathogenesis of nef-deleted HIV.
Attenuation in other HIV genes
In addition to nef and LTR, mutations or polymorphisms
in other HIV genes including gag, rev, tat, vif, vpr, vpu and
env have been detected in SP or LTNP [71-78]. A previous
study of HIV rev alleles isolated from a subject with long-
term nonprogressive HIV infection showed a persistent
Leu to Ile change at position 78 in the Rev activation
domain which attenuated Rev function and HIV replica-
tion capacity [73], providing evidence that defective rev
alleles may contribute to long-term survival of HIV infec-
tion in some patients. A subsequent study of naturally
occurring rev alleles with rare sequence variations in the
activation domain showed variable reductions in Rev
activity [79], although it was unclear from this study
whether the observed reductions in Rev activity would be
sufficient to attenuate HIV replication capacity. Of note,Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
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CTL escape mutations in the second coding exon of Tat
have been shown to attenuate virus in vivo, suggesting that
in vivo sequence changes in other regulatory HIV-1 genes
may potentially affect HIV-1 pathogenesis [80]. Since dif-
ferences in HIV pathogenicity in SBBC members could not
be fully explained by alterations in the nef/LTR region [29]
or Env phenotype [40,50], we characterized dominant
HIV-1 rev alleles that persisted in SBBC LTNP (C18, C64)
and SP (C98, D36) [81]. We found that the ability of Rev
derived from D36 and C64 to bind the Rev responsive ele-
ment (RRE) in RNA binding assays was reduced by
approximately 90% compared to Rev derived from NL4-3,
C18 or C98. D36 Rev also had a 50–60% reduction in
ability to express Rev-dependent reporter constructs in
mammalian cells. In contrast, C64 Rev had only margin-
ally decreased Rev function despite attenuated RRE bind-
ing. In D36 and C64, we found that attenuated RRE
binding was associated with rare amino acid changes at 3
highly conserved residues; Gln to Pro at position 74
immediately N-terminal to the Rev activation domain,
and Val to Leu and Ser to Pro at positions 104 and 106 at
the Rev C-terminus, respectively. In D36, reduced Rev
function and altered replication capacity was mapped to
an unusual 13 amino acid extension at the Rev C-termi-
nus. However, database analysis of rev sequence demon-
strated that the presence of one or more of these rare
amino acid changes was not able to discriminate between
subjects with progressive or non-progressive HIV-1 infec-
tion. Moreover, none of these amino acid changes
occurred in a previously identified LTNP with defective rev
alleles [73]. Thus, our studies suggest the contribution of
any or all of these mutations to decreased RRE binding
and/or attenuated Rev function by SBBC Revs, and possi-
bly to slow or absent HIV progression, is likely to be con-
text dependent.
It is presently unclear whether attenuated D36 Rev func-
tion in vitro equates to attenuated Rev function in vivo, and
indeed whether attenuated Rev function contributed to
slow progression of HIV infection in this subject. Extrapo-
lation of these in vitro findings to an in vivo role for atten-
uated D36 rev alleles is difficult, since this subject and
other SBBC members are infected with virus containing
gross nef/LTR deletions which have been shown to cause
significant viral attenuation in this cohort [28,29,32].
Nonetheless, our findings raise the possibility that attenu-
ated Rev function may contribute, at least in part, to viral
attenuation and slow HIV progression in D36.
Anti-HIV Ig responses
To better understand the humoral immune response to
nef-deleted HIV infection, we measured the total IgG
responses in longitudinal plasma samples of SBBC mem-
bers by Western blotting, and compared these with total
IgG responses in a control group of LTNP with intact nef
genes [40]. We found a good correlation between total
IgG responses in SBBC members and a detectable plasma
VL, with plasma from C18, C54, D36 and C98 all being
strongly reactive. Subjects C49 and C64, who consistently
maintained undetectable HIV RNA copy numbers
[29,30], had significantly reduced total IgG responses.
Furthermore, subject C135, who has also had consistently
undetectable HIV RNA levels has not fully seroconverted
after more than 20 years of infection [40,42]. These stud-
ies highlight the importance of adequate antigenic stimu-
lation by nef-deleted HIV to drive antibody production. In
contrast, we found that total IgG responses in the control
group were uniformly potent, reflecting the fact that all
these individuals had detectable VLs. Among SBBC mem-
bers, the strongest antibody responses were observed in
individuals with low but detectable VL set points, less
than approximately 10,000 RNA copies/ml. This is con-
sistent with a recent observation of an undetectable VL
and weak, delayed antibody responses in an unrelated
individual with nef-deleted HIV [34].
Recent studies have highlighted the change in HIV anti-
body responses with respect to antibody isotype switching
after initial infection, in particular IgG3 reactivity to p24
[82,83]. Preliminary WB testing of p24 IgG3 responses in
the SBBC LTNP indicated there was reactivity for those
individuals with the most potent total IgG responses (C18
and C54) (E. Verity, D. McPhee, K. Wilson, and D. Zotos,
unpublished data). This hints at delayed isotype switching
and hence delayed maturation of immune responses for
at least some members of the SBBC.
Neutralization studies of nef-deleted HIV
In additional studies, we determined whether plasma
from SBBC members had differences in ability to neutral-
ize nef-deleted HIV strains. We did this by comparing the
ability of longitudinally collected plasma from SBBC
members or from control LTNP cohort members to neu-
tralize the infectivity of HIV isolated from D36 and C18
[40]. We found that, for SBBC plasmas, neutralization of
D36 or C18 viruses strongly correlated with VL, replica-
tion capacity of the isolated virus, and the strength of anti-
HIV IgG responses. Plasma from SBBC members with
undetectable VL was unable to neutralize the infectivity of
these viruses. In contrast, plasmas from the control LTNP
cohort were able to neutralize the infectivity of SBBC
viruses with titres generally higher than that seen for SBBC
members, but there was no correlation between neutrali-
zation and HIV RNA copy number or IgG responses in the
control LTNP group.
Broad neutralizing antibody responses
A number of studies have suggested an increased fre-
quency of LTNP and long term survivors (LTS) possess
strong, cross-reactive neutralising antibody responses [84-Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
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86]. However, very few studies have investigated antibody
responses in LTNP/LTS infected with nef-deleted HIV,
despite a number of studies showing strong neutralising
antibody responses in macaques infected with nef-deleted
SIV [87-92]. However, studies by Greenough et al., [93]
showed measurable neutralising antibody responses con-
current with a detectable VL for a single individual
infected with nef-defective HIV. We therefore determined
the breadth of neutralizing antibodies against HIV for
SBBC members.
We found that plasma from C18, and to a lesser extent
D36, C54 and C98 were able to potently neutralize the
infectivity of a number of laboratory adapted and primary
HIV strains, but little or no neutralizing activity was evi-
dent in plasma from C49, C64 and C135 [40]. Further
analysis of cross reacting neutralizing antibodies in SBBC
plasma demonstrated that plasma derived from C18 was
able to potently neutralize the infectivity of HIV-1ROK39
(clade A), HIV-1SE364 (clade C), HIV-1BCB93 (clade D), and
HIV-192TH024  (CRF01_AE), while plasma derived from
C98 was able to only weakly neutralize the infectivity of
HIV-1ROK39 and HIV-1SE364 [40].
Together, our studies on antibody responses in SBBC
members demonstrated that infection with nef-deleted
HIV can, in some individuals, induce antibody responses
capable of potently neutralizing a broad range of isolates.
It is possible that the breadth of antibody responses
observed in SBBC members may be associated with unre-
stricted immunoglobulin class switching, which is inhib-
ited by Nef [94]. This would be counterbalanced by the
very low viral replication in vivo (VL) and a detectable IgG3
p24 response for C18 and C54. Hence, the broad anti-
body response may also reflect an early response to infec-
tion. The strongest antibody responses in SBBC members
were observed in individuals with a detectable VL, sup-
porting the model of a VL threshold which must be
reached to provide adequate antigenic stimulation to
drive antibody production [14]. However, this higher
level of virus replication places these individuals at great-
est risk of disease progression. Signs of disease progres-
sion were observed for 2 SBBC members (D36, C98) [28-
30], demonstrating that the potent neutralizing antibody
responses observed did not protect from disease progres-
sion. These results question the effectiveness of a broad
neutralizing antibody response in individuals with estab-
lished infection. However, this does not preclude an
important role for neutralizing antibodies in preventing
initial infection.
T-cell responses
Analysis of cellular immune mechanisms suppressing nef-
deleted virus in SBBC nonprogressors may provide
insights relevant for HIV vaccine design. Several studies
have demonstrated that the presence of a sustained Gag-
specific CD8+ T-cell response is associated with protection
against disease progression in cohorts of LTNP infected
with nef-intact HIV [95-97]. In support, our studies have
also shown that the distinguishing feature of LTNP har-
bouring nef-intact HIV is the predominance of Gag-spe-
cific CD8+ T-cell responses, which decline when these
individuals start to progress (W.B. Dyer et al., manuscript
in preparation). However, novel qualitative and quantita-
tive differences in immune correlates of viral control may
exist in LTNP infected with nef-deleted HIV. Longitudinal
studies of T-cell responses in SBBC members have demon-
strated a dominance of Pol-specific CD8+ T-cell responses
rather than those against Gag [98] and W.B. Dyer et al.,
manuscript in preparation). This suggests that infection
with nef-deleted HIV may give rise to a qualitatively differ-
ent response, although a subset of SBBC members also
had strong CD8+ T-cell responses to Gag [98]. Nonethe-
less, CD8+ T-cell responses to Gag or Pol did not discrim-
inate SBBC LTNP from SP.
In contrast, longitudinal analysis of HIV-specific CD4+ T-
cells showed that all SBBC nonprogressors able to com-
pletely control plasma HIV RNA levels to below detectable
levels (C49, C64 and C135) had persistent and strong T-
helper proliferative responses to HIV p24 antigen,
whereas these responses were absent in all progressors
with persistent viremia (C54, C98 and D36) (Fig. 3). The
notable exception was C18 who had detectable but low
plasma HIV RNA levels without evidence of CD4+ T-cell
loss, and had detectable p24 T-helper responses over a
short period of approximately 12 months leading up to
his non-HIV related death at 83 years of age. In this sub-
ject, the p24 T-helper responses coincided with an expo-
nential increase in CTL responses against Pol antigens,
measured by memory CTL precursor frequency assay [98],
and IFN-gamma ELISPOT responses (W. Dyer, unpub-
lished data). However, it is difficult to interpret the signif-
icance of the T-cell responses in C18 given the short
window of analysis. Together, although derived from a
small cohort of individuals, these results suggest that
immune suppression of nef-deleted HIV-1 by SBBC LTNP
may be dependent upon persistent T-helper responses
irrespective of the CD8+ T-cell and neutralizing antibody
response to viral antigens.
Conclusion
The development of an effective HIV vaccine has been
hampered by the lack of defined correlates of immune
protection against HIV infection. Although nef-deleted
strains of HIV are not suitable as live attenuated HIV vac-
cines due to safety concerns, the only lentiviral vaccines to
date that have generated sterilizing immunity in animals
are those based on live, attenuated viruses. To this end,
studies of SBBC members naturally "vaccinated" with nef-Retrovirology 2007, 4:66 http://www.retrovirology.com/content/4/1/66
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deleted HIV may provide unique insights into protective
immune responses to HIV infection, which may assist the
development of an effective HIV vaccine. As a consortium,
we have been studying nef-deleted HIV infection in the
SBBC for a number of years, linking changes in patho-
genicity  in vivo with viral evolution and immune
responses to infection. The major aim of this review was
to summarize our recently published and unpublished
studies on the SBBC. Together, the studies show that
potent, broadly neutralizing anti-HIV antibodies and
robust CD8+ T-cell responses to HIV infection were not
necessary for long-term control of HIV infection in a sub-
set of SBBC members, and were not sufficient to prevent
HIV sequence evolution, augmentation of pathogenicity
and eventual progression of HIV infection in another sub-
set. However, a strong T-helper proliferative response to
HIV p24 antigen was associated with long-term control of
infection. Variation in the outcome of HIV infection in
this cohort appears to be strongly host-dependent, con-
sistent with other studies with wild-type HIV. Depend-
ence upon the host's unique immune environment also
appears to be important in contributing to control of
infection. This further complicates development of a suc-
cessful vaccine. We hope that results gleaned thus far from
studies of this unique cohort of individuals will provide
HIV vaccine researchers with novel insights into immune
mechanisms that may serve to prevent or control HIV
infection.
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